Acetaminophen and acetylcysteine dose and duration: Past, present and future
Abstract Acetylcysteine has been utilized successfully in the treatment of acetaminophen overdose since the 1970s. Although prospective trials as to efficacy and safety of acetylcysteine were conducted, there were no randomized controlled trials. This commentary addresses the reasons for this, and t...
Uložené v:
| Vydané v: | Clinical toxicology (Philadelphia, Pa.) Ročník 50; číslo 2; s. 91 - 98 |
|---|---|
| Hlavní autori: | , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
England
Informa Healthcare
01.02.2012
Taylor & Francis |
| Predmet: | |
| ISSN: | 1556-3650, 1556-9519, 1556-9519 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Abstract
Acetylcysteine has been utilized successfully in the treatment of acetaminophen overdose since the 1970s. Although prospective trials as to efficacy and safety of acetylcysteine were conducted, there were no randomized controlled trials. This commentary addresses the reasons for this, and the background to choice of dose of acetylcysteine utilized in the oral and IV dosing regimens. Nomograms to predict possible hepatotoxicity based upon time of ingestion of acetaminophen were developed from a relatively arbitrary definition of toxicity as an aspartate aminotransferase/alanine aminotransferase (ALT/AST) greater than 1000 IU/L. While these have proved generally useful, patients still continue to develop hepatic damage after acetaminophen overdose, particularly if they present late after ingestion. The optimum management of these patients remains unclear, and one area of uncertainty is the dose and duration of acetylcysteine in various circumstances. This article discusses the issues that need to be elucidated to better target changes in acetylcysteine dose. The potential for measurements of other markers to improve treatment selection is the subject of further research. |
|---|---|
| AbstractList | Abstract
Acetylcysteine has been utilized successfully in the treatment of acetaminophen overdose since the 1970s. Although prospective trials as to efficacy and safety of acetylcysteine were conducted, there were no randomized controlled trials. This commentary addresses the reasons for this, and the background to choice of dose of acetylcysteine utilized in the oral and IV dosing regimens. Nomograms to predict possible hepatotoxicity based upon time of ingestion of acetaminophen were developed from a relatively arbitrary definition of toxicity as an aspartate aminotransferase/alanine aminotransferase (ALT/AST) greater than 1000 IU/L. While these have proved generally useful, patients still continue to develop hepatic damage after acetaminophen overdose, particularly if they present late after ingestion. The optimum management of these patients remains unclear, and one area of uncertainty is the dose and duration of acetylcysteine in various circumstances. This article discusses the issues that need to be elucidated to better target changes in acetylcysteine dose. The potential for measurements of other markers to improve treatment selection is the subject of further research. Acetylcysteine has been utilized successfully in the treatment of acetaminophen overdose since the 1970s. Although prospective trials as to efficacy and safety of acetylcysteine were conducted, there were no randomized controlled trials. This commentary addresses the reasons for this, and the background to choice of dose of acetylcysteine utilized in the oral and IV dosing regimens. Nomograms to predict possible hepatotoxicity based upon time of ingestion of acetaminophen were developed from a relatively arbitrary definition of toxicity as an aspartate aminotransferase/alanine aminotransferase (ALT/AST) greater than 1000 IU/L. While these have proved generally useful, patients still continue to develop hepatic damage after acetaminophen overdose, particularly if they present late after ingestion. The optimum management of these patients remains unclear, and one area of uncertainty is the dose and duration of acetylcysteine in various circumstances. This article discusses the issues that need to be elucidated to better target changes in acetylcysteine dose. The potential for measurements of other markers to improve treatment selection is the subject of further research. Acetylcysteine has been utilized successfully in the treatment of acetaminophen overdose since the 1970s. Although prospective trials as to efficacy and safety of acetylcysteine were conducted, there were no randomized controlled trials. This commentary addresses the reasons for this, and the background to choice of dose of acetylcysteine utilized in the oral and IV dosing regimens. Nomograms to predict possible hepatotoxicity based upon time of ingestion of acetaminophen were developed from a relatively arbitrary definition of toxicity as an aspartate aminotransferase/alanine aminotransferase (ALT/AST) greater than 1000 IU/L. While these have proved generally useful, patients still continue to develop hepatic damage after acetaminophen overdose, particularly if they present late after ingestion. The optimum management of these patients remains unclear, and one area of uncertainty is the dose and duration of acetylcysteine in various circumstances. This article discusses the issues that need to be elucidated to better target changes in acetylcysteine dose. The potential for measurements of other markers to improve treatment selection is the subject of further research.Acetylcysteine has been utilized successfully in the treatment of acetaminophen overdose since the 1970s. Although prospective trials as to efficacy and safety of acetylcysteine were conducted, there were no randomized controlled trials. This commentary addresses the reasons for this, and the background to choice of dose of acetylcysteine utilized in the oral and IV dosing regimens. Nomograms to predict possible hepatotoxicity based upon time of ingestion of acetaminophen were developed from a relatively arbitrary definition of toxicity as an aspartate aminotransferase/alanine aminotransferase (ALT/AST) greater than 1000 IU/L. While these have proved generally useful, patients still continue to develop hepatic damage after acetaminophen overdose, particularly if they present late after ingestion. The optimum management of these patients remains unclear, and one area of uncertainty is the dose and duration of acetylcysteine in various circumstances. This article discusses the issues that need to be elucidated to better target changes in acetylcysteine dose. The potential for measurements of other markers to improve treatment selection is the subject of further research. |
| Author | Bateman, D Nicholas Rumack, Barry H |
| Author_xml | – sequence: 1 givenname: Barry H surname: Rumack fullname: Rumack, Barry H email: nick.bateman@luht.scot.nhs.uk, nick.bateman@luht.scot.nhs.uk organization: Rocky Mountain Poison and Drug Center – sequence: 2 givenname: D Nicholas surname: Bateman fullname: Bateman, D Nicholas email: nick.bateman@luht.scot.nhs.uk, nick.bateman@luht.scot.nhs.uk organization: NPIS Edinburgh, Royal Infirmary of Edinburgh |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22320209$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkEtrGzEUhUVIaR7tPyhldt3Erp5jK4uUEJK2YGgX7VpcS1dYYUZyJA3B_74ePxbJIl3dy9E5h6vvgpzGFJGQT4xOBaP6K1OqFa2iU04Zn7ZKc8VPyPkoT7Ri-vSwj54zclHKI6ViLjV7T844F5xyqs_J4tZihT7EtF5hbCC6BrbKprObUjFEbFwquNPdkKGGFK-b31DqVbPOWDDW3Zsf6pDxA3nnoSv48TAvyd-H-z93PyaLX99_3t0uJlayWZ2A59q7eSuX6FQLnON8aVtkHqCdSem99EIqjd7N0CP12s0d16CUpoIzL8Ql-bLvXef0NGCppg_FYtdBxDQUozljUs7E6Px8cA7LHp1Z59BD3pgjgK3hem-wOZWS0Rsb6u6bNUPoDKNmpG2OtM1I2-xpb8PyVfjY_5_Yt30sRJ9yD88pd85U2HQp-wzRhjKm32y4edGwQujqykJG85iGHLfw3z7hH2n3qUs |
| CitedBy_id | crossref_primary_10_1038_s41419_019_1365_z crossref_primary_10_1080_15563650_2025_2456116 crossref_primary_10_1542_pir_2016_0130 crossref_primary_10_3390_livers2040032 crossref_primary_10_1007_s00228_017_2277_4 crossref_primary_10_1093_toxsci_kfaa002 crossref_primary_10_1096_fj_202402278RR crossref_primary_10_1039_C9TX00002J crossref_primary_10_1002_ptr_8145 crossref_primary_10_1016_j_clinthera_2015_07_012 crossref_primary_10_3109_15563650_2015_1077968 crossref_primary_10_1080_01480545_2022_2052891 crossref_primary_10_1111_bcpt_14051 crossref_primary_10_1080_15563650_2021_1996591 crossref_primary_10_3389_fphar_2022_828565 crossref_primary_10_3390_livers5020020 crossref_primary_10_14309_ajg_0000000000002340 crossref_primary_10_1080_17425255_2020_1817896 crossref_primary_10_1016_j_ajem_2019_09_026 crossref_primary_10_1055_s_0040_1712158 crossref_primary_10_3109_15563650_2014_902955 crossref_primary_10_1007_s13181_016_0542_z crossref_primary_10_1002_cpt_2888 crossref_primary_10_1007_s13181_021_00822_x crossref_primary_10_1016_j_rce_2023_12_002 crossref_primary_10_1039_D2FO00507G crossref_primary_10_1016_j_intimp_2019_05_010 crossref_primary_10_1093_toxsci_kfad104 crossref_primary_10_1016_S0140_6736_13_62062_0 crossref_primary_10_1089_ars_2021_0102 crossref_primary_10_1186_s40360_021_00547_1 crossref_primary_10_1016_j_clinbiochem_2015_10_005 crossref_primary_10_1111_fcp_12184 crossref_primary_10_1136_bmjopen_2024_097432 crossref_primary_10_1097_TP_0000000000003534 crossref_primary_10_1093_ajhp_zxaf129 crossref_primary_10_1016_j_jhep_2019_10_030 crossref_primary_10_1155_2021_6695967 crossref_primary_10_1007_s00204_023_03478_4 crossref_primary_10_1080_15563650_2021_1984503 crossref_primary_10_1016_j_cotox_2020_03_003 crossref_primary_10_1093_toxsci_kfz077 crossref_primary_10_1111_bcp_12789 crossref_primary_10_1016_j_fct_2018_06_025 crossref_primary_10_1007_s00204_021_03211_z crossref_primary_10_1016_j_jemermed_2015_12_004 crossref_primary_10_1177_0960327118774902 crossref_primary_10_1007_s00204_021_03142_9 crossref_primary_10_3109_15563650_2016_1159309 crossref_primary_10_1080_15563650_2019_1579914 crossref_primary_10_1097_PEC_0000000000000901 crossref_primary_10_1016_j_cgh_2015_06_017 crossref_primary_10_1016_j_ijbiomac_2024_133426 crossref_primary_10_1016_j_jen_2020_02_015 crossref_primary_10_1016_j_emc_2022_01_008 crossref_primary_10_1016_j_jep_2025_120315 crossref_primary_10_1097_01_JAA_0000554235_40113_c5 crossref_primary_10_1155_2022_3672248 crossref_primary_10_3109_15563650_2014_952432 crossref_primary_10_1002_ohn_1272 crossref_primary_10_3109_15563650_2013_844824 crossref_primary_10_1007_s00228_019_02674_5 crossref_primary_10_1111_bcp_12408 crossref_primary_10_3390_livers2030008 crossref_primary_10_1177_2333794X14552897 crossref_primary_10_1080_15563650_2024_2377268 crossref_primary_10_1111_1742_6723_12610 crossref_primary_10_1016_j_bbrc_2024_149880 crossref_primary_10_1016_j_fct_2022_112911 crossref_primary_10_1111_bcp_15596 crossref_primary_10_1177_1535370220977823 crossref_primary_10_1016_j_jhep_2025_05_008 crossref_primary_10_1111_bcp_15199 crossref_primary_10_1002_hep_26044 crossref_primary_10_1016_j_ccc_2021_03_005 crossref_primary_10_1186_s40064_016_3240_z crossref_primary_10_1111_bcp_13214 crossref_primary_10_1007_s13181_024_01010_3 crossref_primary_10_1016_j_livres_2019_10_002 crossref_primary_10_1111_bcp_15903 crossref_primary_10_1007_s00204_021_03183_0 crossref_primary_10_1080_24734306_2019_1705596 crossref_primary_10_1002_lary_24360 crossref_primary_10_1002_advs_202306066 crossref_primary_10_1080_17425255_2023_2259787 crossref_primary_10_1002_jbt_23505 crossref_primary_10_1002_hep_27266 crossref_primary_10_1002_jac5_1725 crossref_primary_10_1093_toxsci_kfac057 crossref_primary_10_1016_j_intimp_2020_106435 crossref_primary_10_1016_j_apsb_2021_09_023 crossref_primary_10_1016_j_ebiom_2019_07_054 crossref_primary_10_1016_j_bcp_2024_116056 crossref_primary_10_1177_0960327114565494 crossref_primary_10_18359_rmed_5770 crossref_primary_10_5694_mja2_50428 crossref_primary_10_1007_s00204_023_03499_z crossref_primary_10_1097_FAD_0000000000000015 crossref_primary_10_1016_j_tox_2023_153692 crossref_primary_10_1080_15563650_2017_1334915 crossref_primary_10_1016_j_bbrc_2023_02_043 crossref_primary_10_1007_s00210_025_03869_7 crossref_primary_10_1124_dmd_123_001279 crossref_primary_10_1146_annurev_pathmechdis_051122_094016 crossref_primary_10_1177_0960327114531993 crossref_primary_10_1016_j_toxlet_2022_07_813 crossref_primary_10_1111_bcp_13279 crossref_primary_10_1016_j_rceng_2023_12_011 crossref_primary_10_1016_j_cld_2018_06_009 crossref_primary_10_1542_peds_2022_061033 crossref_primary_10_1080_15563650_2018_1529320 crossref_primary_10_1080_15563650_2021_1979232 crossref_primary_10_1111_bcp_15201 crossref_primary_10_3109_15563650_2015_1115057 crossref_primary_10_1080_15563650_2023_2293452 crossref_primary_10_1111_bcp_14755 crossref_primary_10_37349_edd_2025_100569 crossref_primary_10_1080_15563650_2017_1317349 crossref_primary_10_1093_qjmed_hct062 crossref_primary_10_1093_toxsci_kfaf113 crossref_primary_10_3390_pharmaceutics14091800 crossref_primary_10_1517_17425255_2012_724060 crossref_primary_10_1007_s43450_023_00376_9 crossref_primary_10_1111_bcp_12604 crossref_primary_10_1080_15563650_2017_1339887 crossref_primary_10_1080_15563650_2020_1722150 crossref_primary_10_1016_j_jpha_2023_08_004 |
| Cites_doi | 10.1136/bmj.303.6809.1026 10.1016/S0140-6736(76)90030-1 10.1056/NEJM197612022952306 10.1172/JCI110170 10.1542/peds.62.5S.898 10.1159/000136531 10.1002/cpt1974164676 10.1186/1471-230X-11-20 10.1080/15563650802245497 10.1136/bmj.2218 10.1056/NEJM198812153192401 10.1002/hep.24538 10.1001/archinte.1981.00340030112020 10.1016/j.annemergmed.2009.05.010 10.1111/j.1365-2125.1980.tb01812.x 10.1016/j.annemergmed.2007.01.015 10.1016/0140-6736(90)91388-Q 10.1016/j.annemergmed.2004.08.040 10.1136/bmj.2.6198.1097 10.1136/bmj.316.7146.1724 10.1002/9780470122778.ch5 10.3109/15563657308991037 10.1007/BF03178264 10.1177/096032719000900106 10.1136/bmj.317.7173.1609 10.1097/00003246-199801000-00014 10.1186/cc7782 10.1081/CLT-120002882 10.1093/qjmed/hcm003 10.4049/jimmunol.1100165 10.1542/peds.55.6.871 10.1016/S0140-6736(76)92842-7 10.1016/S0140-6736(74)92649-X 10.1111/j.1553-2712.2008.00296.x 10.1016/S0140-6736(76)90105-7 10.1159/000136547 |
| ContentType | Journal Article |
| Copyright | 2012 Informa Healthcare USA, Inc. 2012 |
| Copyright_xml | – notice: 2012 Informa Healthcare USA, Inc. 2012 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.3109/15563650.2012.659252 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Public Health |
| EISSN | 1556-9519 |
| EndPage | 98 |
| ExternalDocumentID | 22320209 10_3109_15563650_2012_659252 659252 |
| Genre | Commentary Journal Article Review |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GroupedDBID | --- .GJ 00X 03L 0BK 0R~ 29B 34G 36B 39C 3O- 4.4 53G 5RE 5VS AAJNR AALIY AALUX AAMIU AAPUL AAQRR ABBKH ABCRQ ABDBF ABEIZ ABLKL ABPTK ABUPF ACENM ACFUF ACGFS ACLSK ADCVX ADFCX ADRBQ AECIN AENEX AEOZL AEYQI AFKVX AFWLO AGAFX AGDLA AGFJD AGRBW AGYJP AIJEM AIRBT AJEBJ AJWEG AKBVH ALIIL ALMA_UNASSIGNED_HOLDINGS ALQZU AWYRJ BABNJ BLEHA BOHLJ CAG CCCUG COF DEIEU DKSSO DTRLO DU5 DZHFC EAP EAS EBC EBD EBS EDH EHN EJD EMB EMK EMOBN EPL EPT ESX F5P H13 HZ~ J.N KRBQP KSSTO KWAYT KYCEM LJTGL LSO M44 M4Z O9- QRXOQ Q~Q RNANH RVRKI SV3 TFDNU TFL TFW TUS UHWXJ V1S ~1N AAGDL ABJNI ABLIJ ABWVI ABXYU ACIEZ ACUHS AFRVT ALYBC AQTUD TASJS TBQAZ TDBHL TERGH TUROJ AARSK AAYXX ACKYO AHZWE BANNL CITATION NUSFT RIG ADYSH CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c417t-af29fd864bed56a22e8bc6e1faa6744ff4f3459efd7efe0f9d8d29a5590321f33 |
| IEDL.DBID | TFW |
| ISICitedReferencesCount | 150 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000300257400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1556-3650 1556-9519 |
| IngestDate | Thu Oct 02 10:36:11 EDT 2025 Thu Apr 03 06:57:18 EDT 2025 Sat Nov 29 02:51:42 EST 2025 Tue Nov 18 21:09:15 EST 2025 Mon Oct 20 23:31:21 EDT 2025 Wed Jun 21 01:44:18 EDT 2023 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c417t-af29fd864bed56a22e8bc6e1faa6744ff4f3459efd7efe0f9d8d29a5590321f33 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 22320209 |
| PQID | 921144733 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | crossref_citationtrail_10_3109_15563650_2012_659252 informahealthcare_journals_10_3109_15563650_2012_659252 crossref_primary_10_3109_15563650_2012_659252 pubmed_primary_22320209 informaworld_taylorfrancis_310_3109_15563650_2012_659252 proquest_miscellaneous_921144733 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-02-01 |
| PublicationDateYYYYMMDD | 2012-02-01 |
| PublicationDate_xml | – month: 02 year: 2012 text: 2012-02-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Clinical toxicology (Philadelphia, Pa.) |
| PublicationTitleAlternate | Clin Toxicol (Phila) |
| PublicationYear | 2012 |
| Publisher | Informa Healthcare Taylor & Francis |
| Publisher_xml | – name: Informa Healthcare – name: Taylor & Francis |
| References | Mitchell JR (CIT0007) 1974; 16 CIT0030 CIT0010 CIT0032 Potter WZ (CIT0005) 1973; 187 Rumack BH (CIT0018) 1978; 62 CIT0031 CIT0012 CIT0034 CIT0033 Rumack BH (CIT0015) 1975; 55 Mitchell JR (CIT0003) 1973; 187 CIT0014 CIT0036 CIT0013 CIT0035 Mitchell JR (CIT0004) 1973; 187 CIT0016 CIT0038 CIT0037 CIT0039 CIT0019 CIT0041 CIT0040 CIT0021 CIT0020 CIT0023 Piperno E (CIT0011) 1978; 62 CIT0022 Jollow DJ (CIT0001) 1973; 187 Boyland E (CIT0017) 1969; 32 CIT0025 CIT0002 CIT0024 CIT0027 CIT0026 CIT0029 CIT0006 CIT0028 CIT0009 CIT0008 33576263 - Clin Toxicol (Phila). 2021 Apr;59(4):359 33988061 - Clin Toxicol (Phila). 2021 May 14;:1 |
| References_xml | – ident: CIT0035 doi: 10.1136/bmj.303.6809.1026 – ident: CIT0010 doi: 10.1016/S0140-6736(76)90030-1 – volume: 62 start-page: 880 year: 1978 ident: CIT0011 publication-title: Pediatrics – ident: CIT0013 doi: 10.1056/NEJM197612022952306 – ident: CIT0020 doi: 10.1172/JCI110170 – volume: 62 start-page: 898 year: 1978 ident: CIT0018 publication-title: Pediatrics doi: 10.1542/peds.62.5S.898 – volume: 187 start-page: 195 year: 1973 ident: CIT0001 publication-title: J Pharmacol Exp Therapeut – ident: CIT0006 doi: 10.1159/000136531 – volume: 16 start-page: 676 year: 1974 ident: CIT0007 publication-title: Clin Pharmacol Therapeut doi: 10.1002/cpt1974164676 – ident: CIT0038 doi: 10.1186/1471-230X-11-20 – ident: CIT0041 doi: 10.1080/15563650802245497 – ident: CIT0022 doi: 10.1136/bmj.2218 – ident: CIT0023 doi: 10.1056/NEJM198812153192401 – volume: 187 start-page: 211 year: 1973 ident: CIT0003 publication-title: J Pharmacol Exp Therapeut – ident: CIT0039 doi: 10.1002/hep.24538 – ident: CIT0016 doi: 10.1001/archinte.1981.00340030112020 – ident: CIT0024 doi: 10.1016/j.annemergmed.2009.05.010 – volume: 187 start-page: 185 year: 1973 ident: CIT0004 publication-title: J Pharmacol Exp Therapeut – ident: CIT0019 doi: 10.1111/j.1365-2125.1980.tb01812.x – ident: CIT0030 doi: 10.1016/j.annemergmed.2007.01.015 – ident: CIT0033 doi: 10.1016/0140-6736(90)91388-Q – ident: CIT0040 doi: 10.1016/j.annemergmed.2004.08.040 – ident: CIT0021 doi: 10.1136/bmj.2.6198.1097 – volume: 187 start-page: 203 year: 1973 ident: CIT0005 publication-title: J Pharmacol Exp Therapeut – ident: CIT0028 doi: 10.1136/bmj.316.7146.1724 – volume: 32 start-page: 173 year: 1969 ident: CIT0017 publication-title: Adv Enzymol Relat Areas Mol Biol doi: 10.1002/9780470122778.ch5 – ident: CIT0009 doi: 10.3109/15563657308991037 – ident: CIT0031 doi: 10.1007/BF03178264 – ident: CIT0034 doi: 10.1177/096032719000900106 – ident: CIT0027 doi: 10.1136/bmj.317.7173.1609 – ident: CIT0029 doi: 10.1097/00003246-199801000-00014 – ident: CIT0036 doi: 10.1186/cc7782 – ident: CIT0025 doi: 10.1081/CLT-120002882 – ident: CIT0026 doi: 10.1093/qjmed/hcm003 – ident: CIT0037 doi: 10.4049/jimmunol.1100165 – volume: 55 start-page: 871 year: 1975 ident: CIT0015 publication-title: Pediatrics doi: 10.1542/peds.55.6.871 – ident: CIT0012 doi: 10.1016/S0140-6736(76)92842-7 – ident: CIT0008 doi: 10.1016/S0140-6736(74)92649-X – ident: CIT0032 doi: 10.1111/j.1553-2712.2008.00296.x – ident: CIT0014 doi: 10.1016/S0140-6736(76)90105-7 – ident: CIT0002 doi: 10.1159/000136547 – reference: 33988061 - Clin Toxicol (Phila). 2021 May 14;:1 – reference: 33576263 - Clin Toxicol (Phila). 2021 Apr;59(4):359 |
| SSID | ssj0038491 |
| Score | 2.392189 |
| SecondaryResourceType | review_article |
| Snippet | Abstract
Acetylcysteine has been utilized successfully in the treatment of acetaminophen overdose since the 1970s. Although prospective trials as to efficacy... Acetylcysteine has been utilized successfully in the treatment of acetaminophen overdose since the 1970s. Although prospective trials as to efficacy and safety... |
| SourceID | proquest pubmed crossref informaworld informahealthcare |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 91 |
| SubjectTerms | Acetaminophen - poisoning Acetylcysteine Acetylcysteine - administration & dosage Antidotes Drug Overdose Humans Multicenter Studies as Topic Paracetamol United States United States Food and Drug Administration |
| Title | Acetaminophen and acetylcysteine dose and duration: Past, present and future |
| URI | https://www.tandfonline.com/doi/abs/10.3109/15563650.2012.659252 https://www.ncbi.nlm.nih.gov/pubmed/22320209 https://www.proquest.com/docview/921144733 |
| Volume | 50 |
| WOSCitedRecordID | wos000300257400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAWR databaseName: Taylor and Francis Online Journals customDbUrl: eissn: 1556-9519 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0038491 issn: 1556-3650 databaseCode: TFW dateStart: 20050101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA4qHgTx_Vhf5ODR6m5eTbyJuHgQ8aC4t5A2CS6sXbFdwX9vpukuPlgX9Ni005DJTDKTzHyD0LGQVBLFVMKYDQ6KtDwxRLYTYii1ggmvMlYXm0hvb2Wvp-4-ZfFDWCX40D4CRdRrNSi3yeoKJIBjedYBUKtgWUBgFjmFe0EOi3DY-aGEwX33cbwUU8lUBEzlIgGKmDs39Sdf9qa1Brn0aRKH9Q3NdLpNWu9N3dX_j2oNrTR2Kb6IgrSO5lyxgZbjoR6OuUqb6OYid5V57hcARlDg0BU2oeV9kAMedOgS22Hp6nY7iqJ1ju9MWZ3gl5jmVL-LOCZb6KF7dX95nTTlGJKcddIqMZ4ob6VgmbNcGEKczHLhOt4YkTLmPfOUceW8TZ13ba-stESZ4LK0Kel4SrfRQjEs3C7CnHtpg-lAhbeMh0XEE6sMc5JnNiPKthAdT4TOG6xyKJkx0MFnAW7pMbc0cEtHbrVQMqF6iVgdM75Pf8yxblS4nEEpP0uCrurTFR9LoQDZb6R4LDU6aDJcz5jCDUelVsEXZyyltIV2ojRNRhFsOBLserX393730RI8xYDzA7RQvY7cIVrM36p--XqE5tOePKqV5wPDIhE6 |
| linkProvider | Taylor & Francis |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LSwMxEA6igoL4ftRnDh5dbfPaxJuIpWItPVTsLWQ3CRZ0K-5W8N-bbLbFB1oQr8nOhkxmJjPJ5BsAjhnHHAkiIkK0C1C4ppFCvB4hhbFmhFmRkLLYRNzp8H5fdKtswrxKq_QxtA1AEaWt9srtD6PPyhCzLs4aHtXKuRY-Mwud-otB6qzwHHVbrRfyXvN-bIwxJyJAplIWeZLweu7Hv3zanVYr7NKHSSbWFzzTn73ScndqrvzDvFbBcuWawosgS2tgxmTrYCmc68HwXGkDtC9SU6inQebxCDLoxoLKtbw9ph4S2o0J9TA3ZbseBek6h12VFyfwObx0KvsClMkmuGte9S5bUVWRIUpJIy4iZZGwmjOSGE2ZQsjwJGWmYZViMSHWEosJFcbq2FhTt0JzjYRyUUsdo4bFeAvMZsPM7ABIqeXaeQ-YWU2osyMWaaGI4TTRCRK6BvB4JWRawZX7qhmP0oUtnltyzC3puSUDt2ogmlA9B7iOKd_H3xZZVlqcT6HkH0VBFuUBiw3VUDzZb6RwLDbSKbO_oVGZGY5yKVw4TkiMcQ1sB3GazMK5cci59mL37-MegYVW77Yt29edmz2w6HtC_vk-mC1eRuYAzKevxSB_OSx16B2g4BR9 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dSyMxEA-iIgfi56n1Mw_36J5tvjbxTdSiKKUPyvkWspsMFnRb3K3gf2-y2Rb18ITzNdnZkMlMMpPM_AahX0JSSRRTCWPWOyjS8sQQ2U6IodQKJkBlrC42kfZ68u5O9d9k8YewyuBDQwSKqPfqoNwjC0e1h9lWR50AauUtixCYRX6Hd0HuN-E5bzmL4H7ddP9M9mIqmYqIqVwkgSQmz336l3eH00oDXXo_DcT6AGf6uVFaH07d5e9PawUtNYYpPomStIpmXLGGFuOtHo7JSuvo-iR3lXkcFAGNoMB-KGx8y8tDHgCh_ZDYDktXt9txlK1j3DdldYhHMc-p7otAJj_Rbff85vQiaeoxJDnrpFVigCiwUrDMWS4MIU5muXAdMEakjAEwoIwrBzZ14NqgrLREGe-ztCnpAKUbaLYYFm4LYc5BWm87UAGWcb-LALHKMCd5ZjOibAvRyULovAErDzUzHrR3WgK39IRbOnBLR261UDKlGkWwji--T_9aY93ocPkFpXwrCbqqr1cg1kIJZP8ixROp0V6Vw_uMKdxwXGrlnXHGUkpbaDNK03QW3ogj3rBX2_8_7gFa6J919fVl72oH_QgdMfh8F81WT2O3h-bz52pQPu3XGvQKQpMTLg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Acetaminophen+and+acetylcysteine+dose+and+duration%3A+Past%2C+present+and+future&rft.jtitle=Clinical+toxicology+%28Philadelphia%2C+Pa.%29&rft.au=Rumack%2C+Barry+H&rft.au=Bateman%2C+D+Nicholas&rft.date=2012-02-01&rft.pub=Taylor+%26+Francis&rft.issn=1556-3650&rft.eissn=1556-9519&rft.volume=50&rft.issue=2&rft.spage=91&rft.epage=98&rft_id=info:doi/10.3109%2F15563650.2012.659252&rft.externalDocID=659252 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1556-3650&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1556-3650&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1556-3650&client=summon |